Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.58 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16596384 | 0.98 | HTR1A (0.61) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL23904665 | 0.82 | CCR1 (0.66) | FERMT2HRH3 | |
| SCHEMBL19563522 | 0.81 | CYP3A4 (0.49) | BRD4BCHE | |
| SCHEMBL19563557 | 0.81 | SMN1; SMN2 (0.60) | HTR1AADRA1DADRA1AADRA1BBRD4 | |
| SCHEMBL24863495 | 0.81 | ACACB (0.55) | BRD4BCHESTK17BSTK17A | |
| SCHEMBL17981164 | 0.80 | PTPN1 (0.56) | HTR1AADRA1DADRA1AADRA1BSTK17A | |
| SCHEMBL20434212 | 0.79 | HTR1A (0.71) | HTR1AADRA1DADRA1AADRA1BBRD4 | |
| SCHEMBL1232778 | 0.79 | STK17B (0.47) | BRD4BCHESTK17BSTK17A | |
| SCHEMBL16585438 | 0.78 | AAK1 (0.48) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL15924004 | 0.78 | HTR1A (0.63) | HTR1AADRA1DADRA1AADRA1BFERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951044-B2 | Quinazoline derivatives and their use as DNA methyltransferase inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2018-04-24 | — | — | US | disclosed |
| EP-3046917-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PF MEDICAMENT (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| WO-2015040169-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2015-03-26 | — | — | WO | disclosed |
| US-8952016-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | DNMT1, DNMT3A, TPMT | HTR1A 2733/4885ADRA1D 3354/4885ADRA1A 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.